Search research articles
Contact Us
Filters
Showing results (61-70 of 69) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 69 results.
Future Oncology (London, England)
|
August 17, 2016
Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research
David F Penson, Daniel W Lin, Lawrence Karsh, et al.
European Urology Focus
|
July 8, 2023
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE)
Max Kates, Xiangying Chu, Noah Hahn, et al.
Endocrinology
|
May 15, 2013
5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models
Khalid Z Masoodi, Raquel Ramos Garcia, Laura E Pascal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 15, 2019
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial
Michael J Morris, Yohann Loriot, Christopher J Sweeney, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 25, 2025
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial
A Tripathi, Y Chen, D F Jarrard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2018
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos E Kyriakopoulos, Yu-Hui Chen, Michael A Carducci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2017
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012
Maha Hussain, Stephanie Daignault-Newton, Przemyslaw W Twardowski, et al.
European Urology Open Science
|
December 22, 2021
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
Karen A Autio, Emmanuel S Antonarakis, Tina M Mayer, et al.
European Urology
|
December 20, 2016
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death
Rong Na, S Lilly Zheng, Misop Han, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 69) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 69 results.
Future Oncology (London, England)
|
August 17, 2016
Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research
David F Penson, Daniel W Lin, Lawrence Karsh, et al.
European Urology Focus
|
July 8, 2023
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE)
Max Kates, Xiangying Chu, Noah Hahn, et al.
Endocrinology
|
May 15, 2013
5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models
Khalid Z Masoodi, Raquel Ramos Garcia, Laura E Pascal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 15, 2019
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial
Michael J Morris, Yohann Loriot, Christopher J Sweeney, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 25, 2025
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial
A Tripathi, Y Chen, D F Jarrard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2018
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos E Kyriakopoulos, Yu-Hui Chen, Michael A Carducci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2017
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012
Maha Hussain, Stephanie Daignault-Newton, Przemyslaw W Twardowski, et al.
European Urology Open Science
|
December 22, 2021
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
Karen A Autio, Emmanuel S Antonarakis, Tina M Mayer, et al.
European Urology
|
December 20, 2016
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death
Rong Na, S Lilly Zheng, Misop Han, et al.
Page
of 7